FDA Grants Priority Review for Roche’s Perjeta in Breast Cancer
Exciting news hit the tape today in the world of breast cancer treatment & heading into the annual Breast Cancer Awareness Month that is kicking off in October. Roche officials reported that the FDA has granted priority review for Roche’s Perjeta specifically in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery. The Reuters article stated that FDA is expected to make a decision on approval by Jan 28, 2018.
The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will die from breast cancer in 2017.
Breast Cancer Awareness Month is an annual campaign to raise awareness of breast cancer risks, the value of screening and early detection, and treatment options available to women and men who are diagnosed with one of the many forms of breast cancer.